Back to All Topics
Myostatin
Research Article
3 min read
ACE-031 Clinical Trial Results
Review of clinical trial outcomes for ACE-031 myostatin inhibitor.
Introduction
ACE-031 was an experimental myostatin inhibitor that underwent clinical trials before development was halted.
ACE-031 Overview
Mechanism
| Feature | Description |
|---|---|
| Type | Soluble ActRIIB receptor |
| Target | Myostatin and related factors |
| Action | Decoy receptor, binds myostatin |
| Administration | Injection |
Clinical Trial History
Phase 1 Studies
| Aspect | Finding |
|---|---|
| Population | Healthy volunteers |
| Dose range | Escalating doses tested |
| Muscle effects | Increased lean mass observed |
| Fat effects | Decreased fat mass |
Phase 2 in DMD
| Aspect | Finding |
|---|---|
| Population | Duchenne muscular dystrophy patients |
| Initial results | Some positive indicators |
| Safety issue | Nosebleeds, gum bleeding |
| Vascular concern | Telangiectasias |
| Outcome | Development halted |
Efficacy Data
Muscle Mass Effects
| Measure | Result | Significance |
|---|---|---|
| Lean body mass | Increased | Clinically meaningful |
| Muscle volume | Increased | Measurable on imaging |
| Fat mass | Decreased | Secondary benefit |
Functional Outcomes
| Measure | Result | Notes |
|---|---|---|
| Strength | Variable | Not consistently improved |
| Function | Mixed | Disease-specific |
Safety Concerns
Issues Leading to Halt
| Issue | Nature | Significance |
|---|---|---|
| Telangiectasias | Dilated blood vessels | Concerning pattern |
| Epistaxis | Nosebleeds | Vascular effect |
| Gingival bleeding | Gum bleeding | Consistent with vascular |
Mechanism of Concern
| Factor | Explanation |
|---|---|
| ActRIIB targets | Multiple ligands beyond myostatin |
| Vascular effects | May affect blood vessel integrity |
| Off-target binding | Broader than myostatin alone |
Lessons Learned
For Drug Development
| Lesson | Implication |
|---|---|
| Selectivity matters | Broad inhibition = side effects |
| Vascular monitoring | Essential for this class |
| Risk-benefit | Must favor benefit significantly |
For Bodybuilding Context
| Consideration | Takeaway |
|---|---|
| Clinical failure | Not suitable for enhancement |
| Safety signals | Serious concerns |
| Alternatives | Other approaches preferable |
Comparison to Other Approaches
| Factor | ACE-031 | GH Peptides | Natural Training |
|---|---|---|---|
| Muscle effect | Potentially strong | Moderate | Proven |
| Safety | Concerns | Established | Excellent |
| Availability | None | Research | Universal |
| Recommendation | Not available | Consider carefully | First line |
Current Status
| Aspect | Status |
|---|---|
| Development | Halted |
| Availability | None |
| Future | Unlikely to resume |
| Research | Lessons applied to new compounds |
Conclusion
ACE-031's development was terminated due to vascular safety concerns despite muscle-building effects.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.